Efficacy and Safety of Intravenous Ferric Carboxymaltose in Geriatric Inpatients at a German Tertiary University Teaching Hospital: A Retrospective Observational Cohort Study of Clinical Practice

Table 3

Amount of iron supplementation and Hb response.

Age group	Calculated iron requirement (mg); mean ± SD; (median; min–max)	Supplemented iron (mg); mean ± SD; (median; min–max)	Number of infusions	Hb BoS (g/dL); mean ± SD; (median; min–max)	Hb EoS (g/dL); mean ± SD; (median; min–max)	Hb (g/dL); mean ± SD; (median; min–max)	% responder; (Hb >1 g/dL)
76–85 years	1210.4 ± 308.4; (1205.6; 1205.6–1724.0)	763.2 ± 297.7; (500; 500–1500)	(1–3)	10.42 ± 0.85; (10.3; 8.8–11.8)	11.31 ± 1.17; (11.9; 9.5–14.3)	0.54 ± 1.49; (0.9; 0.0–3.2)	8/17 (41%)
>85 years	1022.5 ± 263.7; (1046.4; 500.0–1493.6)	770.8 ± 249.1; (500; 500–1000)	(1-2)	11.00 ± 1.52; (10.7; 8.8–13.5)	11.75 ± 0.86; (11.9; 10.2–13)	0.69 ± 1.10; (0.9; 0.0–2.6)	10/21 (48%)
All	1105.6 ± 299.2; (1085.6; 478.2–1724.0)	784.4 ± 271.7; (500; 500–1500)	(1–3)	10.74 ± 1.30; (10.5; 8.8–13.5)	11.68; (11.35; 8.8–14.3)	0.62 ± 1.58; (0.9; 0.0–3.2)	18/38 (47%)

BoS: beginning of study; EoS: end of study.